share_log

BioVie | 424B5: Prospectus

BioVie | 424B5: Prospectus

BioVie | 424B5：募資說明書
美股SEC公告 ·  2024/09/24 16:32

Moomoo AI 已提取核心訊息

BioVie Inc., a clinical-stage company focusing on the development of drug therapies for liver disease and neurological disorders, has announced the offering of 1,360,800 shares of its Class A common stock at a price of $1.53 per share. Additionally, the company is offering pre-funded warrants to purchase up to 600,000 shares of common stock and warrants to purchase up to 1,960,800 shares of common stock. The pre-funded warrants, exercisable at $0.0001 per share, cater to purchasers who would otherwise own more than 4.99% of the issued and outstanding common stock post-offering. The common warrants, exercisable at $1.53 per share, will be immediately exercisable and expire five years from the issuance date. ThinkEquity LLC acts as the exclusive placement agent for the offering. The placement agent will use reasonable best efforts to arrange for the sale of the securities, but is not obligated to sell any specific number or dollar amount. The offering is expected to close on or about September 25, 2024, subject to customary closing conditions.
BioVie Inc., a clinical-stage company focusing on the development of drug therapies for liver disease and neurological disorders, has announced the offering of 1,360,800 shares of its Class A common stock at a price of $1.53 per share. Additionally, the company is offering pre-funded warrants to purchase up to 600,000 shares of common stock and warrants to purchase up to 1,960,800 shares of common stock. The pre-funded warrants, exercisable at $0.0001 per share, cater to purchasers who would otherwise own more than 4.99% of the issued and outstanding common stock post-offering. The common warrants, exercisable at $1.53 per share, will be immediately exercisable and expire five years from the issuance date. ThinkEquity LLC acts as the exclusive placement agent for the offering. The placement agent will use reasonable best efforts to arrange for the sale of the securities, but is not obligated to sell any specific number or dollar amount. The offering is expected to close on or about September 25, 2024, subject to customary closing conditions.
BioVie Inc.是一家臨床階段的公司，專注於開發治療肝病和神經疾病的藥物療法。該公司宣佈以1.53美元每股的價格發行1,360,800股A類普通股。此外，該公司還提供發售預擬定認股權證，用於購買高達600,000股普通股，以及購買高達1,960,800股普通股的認股權證。預擬定認股權證的行使價格爲每股0.0001美元，適用於否則將持有已發行和流通普通股超過4.99%的購買者。普通認股權證的行使價格爲每股1.53美元，將立即行使，並自發行日期起五年後到期。ThinkEquity LLC擔任此次發售的唯一承銷代理。承銷代理將盡力安排出售證券，但並無義務出售任何特定數量或金額。預計本次發行將於2024年9月25日前後結束，視常規閉市條件而定。
BioVie Inc.是一家臨床階段的公司，專注於開發治療肝病和神經疾病的藥物療法。該公司宣佈以1.53美元每股的價格發行1,360,800股A類普通股。此外，該公司還提供發售預擬定認股權證，用於購買高達600,000股普通股，以及購買高達1,960,800股普通股的認股權證。預擬定認股權證的行使價格爲每股0.0001美元，適用於否則將持有已發行和流通普通股超過4.99%的購買者。普通認股權證的行使價格爲每股1.53美元，將立即行使，並自發行日期起五年後到期。ThinkEquity LLC擔任此次發售的唯一承銷代理。承銷代理將盡力安排出售證券，但並無義務出售任何特定數量或金額。預計本次發行將於2024年9月25日前後結束，視常規閉市條件而定。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間